<SEC-DOCUMENT>0001193125-25-131697.txt : 20250530
<SEC-HEADER>0001193125-25-131697.hdr.sgml : 20250530
<ACCEPTANCE-DATETIME>20250530105134
ACCESSION NUMBER:		0001193125-25-131697
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20250530
FILED AS OF DATE:		20250530
DATE AS OF CHANGE:		20250530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		251007840

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d947351d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of May 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In May 2025, Sanofi published the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><U>Exhibit No.</U></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><U>Description</U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><A HREF="d947351dex991.htm">Press Release dated May&nbsp;
27, 2025: Sanofi completes acquisition of <FONT STYLE="white-space:nowrap">DR-0201</FONT> </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><A HREF="d947351dex992.htm">Press Release dated<B> </B>May&nbsp;
29, 2025: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><A HREF="d947351dex993.htm">Press Release dated<B> </B>May&nbsp;30, 2025: Itepekimab met the primary endpoint in one of two COPD phase 3 studies</A></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: May&nbsp;30, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>/s/ <U>Alexandra Roger&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d947351dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g947351g0530164328702.jpg" ALT="LOGO" STYLE="width:1.54306in;height:0.434722in;">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi completes acquisition of DR-0201 </I></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Paris, May</B><B></B><B>&nbsp;27, 2025. </B>Sanofi announces the completion of its acquisition of <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7a00e6"><U><FONT
STYLE="white-space:nowrap">DR-0201</FONT></U></FONT><FONT STYLE="font-family:arial">, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition bolsters Sanofi&#146;s
ambition to become the foremost immunology company and broadens the company&#146;s leading immunology pipeline. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">DR-0201,</FONT> now named SAR448501, has shown robust <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and early clinical studies. The potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> targeted bispecific myeloid cell engager targets and engages
specific tissue-resident and trafficking myeloid cells to induce deep <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion via targeted phagocytosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Recent <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and early clinical study data in autoimmune diseases suggest that deep <FONT STYLE="white-space:nowrap">B-</FONT> cell depletion has the potential to reset the adaptive immune system, leading to
sustained treatment-free remission in patients with refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> mediated autoimmune diseases such as lupus, where significant unmet medical needs remain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi acquired <FONT STYLE="white-space:nowrap">DR-0201</FONT> through the acquisition of the Dren Bio affiliate Dren 0201, Inc. for an upfront payment of
$600&nbsp;million and potential future payments totaling $1.3&nbsp;billion upon achievements of certain development and launch milestones. Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics that
selectively deplete pathogenic cells and other disease-causing agents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">We are
an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into
the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Sandrine Guendoul
</B>| +33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Evan Berland </B>| +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Victor Rouault </B>|
+33 6 70 93 71 40 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Timothy Gilbert </B>| +1 516 521 2929 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Thomas Kudsk Larsen </B>| +44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Aliz&eacute; Kaisserian </B>| +33 6 47 04 12 11 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Felix Lauscher
</B>| +1 908 612 7239 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Keita Browne </B>| +1 781 249 1766 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Nathalie Pham </B>|
+33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Tarik Elgoutni </B>| +1 617 710 3587 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Thibaud Ch&acirc;telet </B>| +33 6 80 80 89 90 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Yun Li </B>| +33 6
84 00 90 72 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><I>Dren Bio </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Jeff Macfarland</B>, EVP, Finance | ir@drenbio.com </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sanofi forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements
are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the
expectations reflected in such forward-looking statements are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g947351g0530164329315.jpg" ALT="LOGO" STYLE="width:0.602083in;height:0.169444in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to
benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with
the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT>
for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g947351g0530164329315.jpg" ALT="LOGO" STYLE="width:0.602083in;height:0.169444in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d947351dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g947351g0530164328702.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Beyfortus public health advantage bolstered by first real- world comparison of infant vs maternal RSV
immunization programs </I></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following
Beyfortus-only immunization targeted to all infants and 26.7% in the UK following RSVpreF-only maternal vaccination </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Newly presented durability data show Beyfortus sustained efficacy of 83% through six months in babies born before or during
the RSV season </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Paris, May</B><B></B><B>&nbsp;29, 2025</B>. An immunization program implemented in Spain using Beyfortus cut infant
hospitalizations due to RSV by 69.0% during the 2024-2025 RSV season compared to the 2022-2023 season, according to data presented at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Bucharest, Romania.
The real- world analysis also showed that a program in the UK using only the RSVpreF maternal vaccine reduced infant RSV hospitalizations in infants by 26.7% over those same RSV seasons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi&#146;s observational, retrospective REACH study is the first multi-country public health impact analysis of infant RSV prevention programs. These late-breaking
data will be presented for the first time today during an oral session (Session 09: Late Breaking) from 2:00 &#150; 3:30 pm EEST at ESPID, which is taking place from May <FONT STYLE="white-space:nowrap">26-30,</FONT> 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other data from Sanofi at ESPID include new durability data from the HARMONIE Phase 3b clinical study, now published in <I>The Lancet Child</I><I></I><I>&nbsp;&amp;
Adolescent Health</I>, that demonstrates Beyfortus reduced RSV hospitalizations in infants by 82.7% (95% CI: 67.8 to 91.5; p&lt;0.0001) through six months (180 days) compared to no intervention, exceeding the typical length of the five-month RSV
season. The high efficacy of 83.2% previously reported in the primary analysis was sustained over the longer <FONT STYLE="white-space:nowrap">follow-up</FONT> period with no evidence of waning protection in infants born before or during the RSV
season. Beyfortus maintained a favorable safety profile, consistent with clinical study results. Those results will be shared in an oral presentation on Friday, May&nbsp;30 from 10:40 &#150; 10:50 EEST (Oral Presentation Session 10: Preventing RSV).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Thomas Triomphe </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Executive Vice President, Vaccines </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I>&#147;The <FONT STYLE="white-space:nowrap">six-month</FONT> data from HARMONIE show Beyfortus&#146; protection exceeded the
typical five- month RSV season. This is important because half of infant RSV hospitalizations occur in older babies born before the RSV season begins. These data demonstrating high, sustained efficacy, combined with real-world public health impact
data, underscore how Beyfortus provides proven protection against the number one cause of lower respiratory tract disease in all infants.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additional
late-breaking data for Beyfortus at ESPID 2025 (Poster presentation #EV1006) reinforce Beyfortus as cost-effective in preventing RSV disease in infants, with results showing Beyfortus prevents more medically attended RSV cases when compared with
clesrovimab, another antibody in development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyfortus has amassed real-world data in over 40 studies spanning four continents and more than 250,000 immunized
infants &#150; the largest body of public health impact data for infant RSV protection across countries, population groups and healthcare settings. With more than six million infants immunized, Beyfortus is well accepted by parents and providers and
remains the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favorable safety and public health impact demonstrated in the real world. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g947351g0530164329315.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About RSV </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">RSV is a highly contagious virus that can lead to serious respiratory illness for infants. Two out of three infants are infected with RSV during their first year of life
and almost all children are infected by their second birthday. RSV is the most common cause of lower respiratory tract disease, including bronchiolitis and pneumonia, in infants. It is also a leading cause of hospitalization in infants worldwide,
with most hospitalizations for RSV occurring in healthy infants born at term. Globally, in 2019, there were approximately 33&nbsp;million cases of acute lower respiratory infections leading to more than three million hospitalizations in children
younger than five years. <FONT STYLE="white-space:nowrap">RSV-related</FONT> direct medical costs, globally &#151; including hospital, outpatient and <FONT STYLE="white-space:nowrap">follow-up</FONT> care &#151; were estimated at c.<FONT
STYLE="font-family:Times New Roman">&#128;</FONT>5&nbsp;billion in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Beyfortus </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyfortus is the first immunization designed for all infants for protection against RSV disease through their first RSV season, including for those born before or during
the RSV season, healthy at term or preterm, or with specific health conditions. Beyfortus is also designed to protect children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a long-acting antibody provided directly to newborns and infants as a single dose, Beyfortus offers rapid and direct protection to help prevent lower respiratory
tract disease caused by RSV without requiring activation of the immune system. Beyfortus administration can be timed to coincide with the RSV season. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beyfortus has
been approved for use in the US, the EU, China, Japan, and many other countries around the world. Special designations to facilitate expedited development of Beyfortus were achieved in several countries, including breakthrough therapy designation
and fast track designation in the US; PRIority MEdicines (PRIME) and accelerated assessment in the EU; &#147;a medicine for prioritized development&#148; in Japan, and breakthrough therapy designation and priority review designation in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About REACH </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The REACH study was
performed on the LOGEX RTI Observatory<I>, </I>ran by healthcare analytics company LOGEX, and used administrative and microbiology data from multiple hospital sites across Spain and the UK. Data collection is ongoing through May 2025, with current
results reflecting three consecutive RSV seasons from June 2022 through the end of March 2025. Hospitals report RSV hospitalizations from the current season as well as historical seasons for each country separately. No RSV prevention program was in
place for the <FONT STYLE="white-space:nowrap">2022-23</FONT> RSV season. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About HARMONIE </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <B>H</B>ospit<B>a</B>lized <B>R</B>SV <B>Mon</B>oclonal Ant<B>i</B>body Pr<B>e</B>vention (HARMONIE) study is a large European Phase 3b clinical trial conducted in
multi-country, close to real-world conditions to reinforce the efficacy and safety of Beyfortus for the prevention of <FONT STYLE="white-space:nowrap">RSV-related</FONT> hospitalizations in infants up to 12 months of age who are not eligible to
receive palivizumab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trial opened at nearly 250 sites and enrolled more than 8,000 infants born with a gestational age of 29 weeks or greater during the
2022-2023 RSV season. Primary results from the study published in <I>The New England Journal of Medicine </I>(NEJM) confirmed efficacy of 83.2% (95% CI 67.8 to 92.0; P&lt;0.001) for Beyfortus against
<FONT STYLE="white-space:nowrap">RSV-related</FONT> hospitalizations and efficacy of 75.7% (95% CI: 32.8 to 92.9; P=0.004) against very severe RSV lower respiratory tract disease compared to no RSV intervention (standard of care) through the RSV
season. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi is an R&amp;D
driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#146;s lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat
and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people&#146;s lives; this inspires us to drive progress and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g947351g0530164329315.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare,
environmental, and societal challenges of our time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine Guendoul
</B>| +33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland </B>| +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;o Le Bourhis
</B>| +33 6 75 06 43 81 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault </B>| +33 6 70 93 71 40 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert </B>| +1 516 521 2929 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas Kudsk Larsen </B>|+44 7545 513 693 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute;
Kaisserian </B>| +33 6 47 04 12 11 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix Lauscher </B>| +1 908 612 7239 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita Browne </B>| +1 781 249 1766 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham </B>|
+33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>| +1 617 710 3587 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud Ch&acirc;telet </B>| +33 6 80 80 89 90 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Yun Li </B>| +33 6
84 00 90 72 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other
potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;,
&#147;estimates&#148;, &#147;plans&#148;, and similar expressions. Although Sanofi&#146;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information
and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product,
including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic
and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding
Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to
update or revise any forward-looking information or statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial">All trademarks mentioned in this press release are the property of the Sanofi group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g947351g0530164329315.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d947351dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g947351g0530164748024.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Itepekimab met the primary endpoint in one of two COPD phase 3 studies </I></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">AERIFY-1</FONT> study met its primary endpoint of a statistically significant reduction in
moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">AERIFY-2</FONT> study, a second Phase 3 study, did not meet the primary endpoint despite a
benefit seen earlier in the study </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Itepekimab was generally well tolerated in both <FONT STYLE="white-space:nowrap">AERIFY-1</FONT> and AERIFY-2
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Sanofi and Regeneron are assessing the data and will discuss with regulatory authorities to evaluate next steps
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Paris and Tarrytown, NY, May</B><B></B><B>&nbsp;30, 2025. </B>The <FONT STYLE="white-space:nowrap">AERIFY-1</FONT> phase 3 study evaluating
itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant reduction in moderate or severe acute exacerbations compared to placebo of 27% at week 52,
a clinically meaningful benefit. The <FONT STYLE="white-space:nowrap">AERIFY-2</FONT> phase 3 study did not meet the same primary endpoint, although a benefit was seen earlier in the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the studies, patients were randomized to receive itepekimab every two weeks <FONT STYLE="white-space:nowrap">(AERIFY-1:</FONT> n=375;
<FONT STYLE="white-space:nowrap">AERIFY-2:</FONT> n=326), every four weeks <FONT STYLE="white-space:nowrap">(AERIFY-1:</FONT> n=377; <FONT STYLE="white-space:nowrap">AERIFY-2:</FONT> n=303), or placebo
<FONT STYLE="white-space:nowrap">(AERIFY-1:</FONT> n=375; <FONT STYLE="white-space:nowrap">AERIFY-2:</FONT> n=324), which was added to inhaled triple or double
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapy. The primary endpoint analysis for <FONT STYLE="white-space:nowrap">AERIFY-1</FONT> and <FONT STYLE="white-space:nowrap">AERIFY-2</FONT> was the
reduction in the annualized rate of acute moderate or severe COPD exacerbations with itepekimab treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The table below summarizes the reductions in moderate or
severe exacerbations (itepekimab compared to placebo) through weeks 24 and 52: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BGCOLOR="#e1f2fa">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; "><B>AERIFY-1</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT STYLE="font-family:Arial Narrow; "><B>AERIFY-2</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; "><I>Week 24</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; "><I>Week 52</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; "><I>Week 24</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT STYLE="font-family:Arial Narrow; "><I>Week 52</I></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow">Itepekimab</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Arial Narrow">every two weeks</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; ">30%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; ">27%<SUP STYLE="font-size:75%; vertical-align:top">a</SUP></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; ">18%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT STYLE="font-family:Arial Narrow; ">2%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow">Itepekimab every&nbsp;four</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Arial Narrow">weeks</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; ">34%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; ">21%<SUP STYLE="font-size:75%; vertical-align:top">a</SUP></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Arial Narrow; ">21%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT STYLE="font-family:Arial Narrow; ">12%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">a</SUP> Formal significance testing was only performed at 52 weeks in the Phase 3 trials,
with significance achieved for both the every <FONT STYLE="white-space:nowrap">two-week</FONT> arm and every four-week arm in <FONT STYLE="white-space:nowrap">AERIFY-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The total number of exacerbations were lower than prospectively anticipated, decreasing the power of both trials. Enrollment largely occurred during the time of the
global COVID pandemic, which could have contributed to the overall lower exacerbation rates. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Houman Ashrafian, MD, PhD </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:arial">Executive Vice President, Head of Research and Development at Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I>&#147;While we are encouraged by the results of <FONT STYLE="white-space:nowrap">AERIFY-1,</FONT> the results of both
studies merit further exploration to have a full understanding of the data and the role that IL33 plays in this complex disease. Certain people with COPD are in desperate need of new treatment options, especially those who continue to experience
exacerbations despite being on maximal therapy, and we remain committed to discussing these data with regulatory agencies to evaluate our path forward.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The safety profile of itepekimab was consistent across dosing regimens, and adverse events (AEs) were generally comparable between treatment and placebo groups. In <FONT
STYLE="white-space:nowrap">AERIFY-1,</FONT> the overall rates of AEs were 67% and 68% for itepekimab every two weeks and every four weeks, respectively, compared to 68% for placebo. In <FONT STYLE="white-space:nowrap">AERIFY-2,</FONT> the overall
rates of AEs were 64% and 71% for itepekimab every two weeks and every four weeks, respectively, compared to 64% for placebo. In <FONT STYLE="white-space:nowrap">AERIFY-1,</FONT> the rate of serious infections was 7% for each itepekimab arm,
compared to 10% for placebo. In <FONT STYLE="white-space:nowrap">AERIFY-2,</FONT> the rate of serious infections was 10% and 7% for itepekimab every two weeks and every four weeks, respectively, compared to 7% for placebo. AEs leading to death were
1% for each itepekimab arm compared to 2% for placebo in <FONT STYLE="white-space:nowrap">AERIFY-1,</FONT> and 3% for each itepekimab arm compared to 2% for placebo in <FONT STYLE="white-space:nowrap">AERIFY-2.</FONT> Anti-drug antibodies were rare
and had no apparent impact on itepekimab drug levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi and Regeneron are reviewing the data and will discuss with regulatory authorities to evaluate next
steps. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Detailed results from these studies will be presented at a future medical meeting. Itepekimab is currently being evaluated in other studies, including
chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP), and bronchiectasis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><B><I>George D. Yancopoulos, M.D., Ph.D. </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:arial">Board <FONT STYLE="white-space:nowrap">co-Chair,</FONT>
President and Chief Scientific Officer at Regeneron </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I>&#147;COPD is a particularly complex disease, and novel approaches
are needed to address the multiple underlying biological disease driver. We are proud of our work in this challenging treatment landscape, bringing Dupixent &#150; the first-ever biologic medicine for COPD &#150; to certain patients who previously
had very limited options remaining. We are encouraged by the initial results from <FONT STYLE="white-space:nowrap">AERIFY-1</FONT> and are carefully reviewing the results from both itepekimab trials to inform next steps. We remain committed to our
broader itepekimab development program. The learnings will be invaluable as we continue to advance itepekimab in respiratory diseases with unmet need.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The safety and efficacy of itepekimab are currently under clinical investigation and have not been fully evaluated by any regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About itepekimab </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Itepekimab is a fully
human monoclonal antibody that binds to and inhibits <FONT STYLE="white-space:nowrap">interleukin-33</FONT> (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be involved in different types of inflammation and is
particularly elevated in the lungs of former smokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Itepekimab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement and is
currently in clinical development programs for CRSwNP (phase 3), <FONT STYLE="white-space:nowrap">non-cystic</FONT> fibrosis bronchiectasis (phase 2), and CRSsNP (phase 2). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About the AERIFY clinical study program </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><FONT STYLE="white-space:nowrap">AERIFY-1</FONT> and <FONT STYLE="white-space:nowrap">AERIFY-2</FONT> phase 3 studies were randomized, Phase 3, double-blind,
placebo-controlled studies that evaluated the efficacy and safety of itepekimab in 1,127 <FONT STYLE="white-space:nowrap">(AERIFY-1)</FONT> and 953 <FONT STYLE="white-space:nowrap">(AERIFY-2)</FONT> adults aged
<FONT STYLE="white-space:nowrap">40-85</FONT> years </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">who were former smokers with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> COPD. Former smokers were defined as those who have not smoked for at least six months. Treatments were administered subcutaneously and added to
double therapy (inhaled corticosteroid [ICS] plus long-acting beta2-agonist [LABA] or long-acting muscarinic antagonist [LAMA] plus LABA) or a maximal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT>
inhaled triple therapy (ICS, LABA and LAMA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">The primary endpoint for <FONT STYLE="white-space:nowrap">AERIFY-1</FONT> and
<FONT STYLE="white-space:nowrap">AERIFY-2</FONT> was the annualized rate of acute moderate or severe COPD exacerbations. Moderate exacerbations were defined as those requiring systemic steroids and/or antibiotics. Severe exacerbations, also assessed
separately as a <FONT STYLE="white-space:nowrap">pre-specified</FONT> endpoint, were defined as those: requiring hospitalization; more than 24 hours of observation in an emergency department or urgent care facility; or resulting in death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">The AERIFY program includes two additional ongoing trials: <FONT STYLE="white-space:nowrap">AERIFY-3,</FONT> a Phase 2 mechanistic study assessing the impact of
itepekimab on airway inflammation in patients with COPD, and <FONT STYLE="white-space:nowrap">AERIFY-4,</FONT> a Phase 3 study assessing the long-term safety of itepekimab in patients with COPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is an R&amp;D
driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#146;s lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat
and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people&#146;s lives; this inspires us to drive progress and
deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Regeneron </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents, develops and commercializes life- transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate
science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as <I>VelociSuite</I><I><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I>, </I>which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron
Genetics Center<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">For more information, please visit <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#0563c1"><U>www.Regeneron.com</U></FONT><FONT STYLE="font-family:arial"> or
follow Regeneron on </FONT><FONT STYLE="font-family:arial; font-size:8pt" COLOR="#0563c1"><U>LinkedIn</U></FONT><FONT STYLE="font-family:arial">, </FONT><FONT STYLE="font-family:arial; font-size:8pt" COLOR="#0563c1"><U>Instagram</U></FONT><FONT
STYLE="font-family:arial">, </FONT><FONT STYLE="font-family:arial; font-size:8pt" COLOR="#0563c1"><U>Facebook </U></FONT><FONT STYLE="font-family:arial">or </FONT><FONT STYLE="font-family:arial; font-size:8pt" COLOR="#0563c1"><U>X</U></FONT><FONT
STYLE="font-family:arial">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine Guendoul </B>| +33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland </B>| +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;o Le Bourhis
</B>| +33 6 75 06 43 81 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault </B>| +33 6 70 93 71 40 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert </B>| +1 516 521 2929 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;a Ubaldi
</B>| +33 6 30 19 66 46 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>lea.ubaldi@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas
Kudsk Larsen </B>|+44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute; Kaisserian </B>| +33 6 47 04 12 11 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix Lauscher </B>| +1 908 612 7239 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita Browne </B>|
+1 781 249 1766 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham </B>| +33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>| +1 617 710 3587 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud
Ch&acirc;telet </B>| +33 6 80 80 89 90 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Yun Li </B>| +33 6 84 00 90 72 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:arial">
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Regeneron Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Hannah Kwagh </B>| +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">914-847-6314|</FONT></FONT> <FONT
STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>hannah.kwagh@regeneron.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><I>Regeneron Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Mark Hudson </B>| +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">914-847-3482</FONT></FONT> | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>mark.hudson@regeneron.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi forward-looking statements </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the
product. Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148;, and similar expressions. Although
Sanofi&#146;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be
commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing
issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us,
our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward- Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial">All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Regeneron forward-looking statements and use of digital media </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">This press
release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148; or the &#147;Company&#148;), and actual events or results
may differ materially from these forward-looking statements. Words such as &#147;anticipate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; variations of such words, and
similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature,
timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Products&#148;) and product candidates being
developed by Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Product Candidates&#148;) and research and clinical programs now underway or planned, including without limitation itepekimab in adults who were
former smokers with inadequately controlled chronic obstructive pulmonary disease (&#147;COPD&#148;) and other potential indications; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron&#146;s Product
Candidates and new indications for Regeneron&#146;s Products, such as itepekimab for the treatment of COPD as discussed in this press release as well as itepekimab for the treatment of chronic rhinosinusitis with nasal polyps, <FONT
STYLE="white-space:nowrap">non-cystic</FONT> fibrosis bronchiectasis, and chronic rhinosinusitis without nasal polyps; any feedback that may be provided by regulatory authorities on the results from the
<FONT STYLE="white-space:nowrap">AERIFY-1</FONT> and <FONT STYLE="white-space:nowrap">AERIFY-2</FONT> trials discussed in this press release, including the impact of any such feedback on any potential regulatory approval of itepekimab; uncertainty
of the utilization, market acceptance, and commercial success of Regeneron&#146;s Products and Regeneron&#146;s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the
studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron&#146;s Products and Regeneron&#146;s Product Candidates (such as itepekimab); the ability of Regeneron&#146;s
collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron&#146;s Products and Regeneron&#146;s Product
Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron&#146;s Products
and Regeneron&#146;s Product Candidates (such as itepekimab) in patients, including serious complications or side effects in connection with the use of Regeneron&#146;s Products and Regeneron&#146;s Product Candidates in clinical trials;
determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron&#146;s ability to continue to develop or commercialize Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; ongoing
regulatory obligations and oversight impacting Regeneron&#146;s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for
Regeneron&#146;s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare
and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare
industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron&#146;s Products and Regeneron&#146;s Product Candidates (including biosimilar versions of Regeneron&#146;s Products); the extent to
which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic
applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those
projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron&#146;s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the
impact of public health outbreaks, epidemics, or pandemics on Regeneron&#146;s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending
civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney&#146;s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating
thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (aflibercept) Injection), the ultimate outcome of any such proceedings and
investigations, and the impact any of the foregoing may have on Regeneron&#146;s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron&#146;s filings
with the U.S. Securities and Exchange Commission, including its Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 and its Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended
March&nbsp;31, 2025. Any forward-looking statements are made based on management&#146;s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any
obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">Regeneron uses its media and investor relations website and social media outlets to publish important information about
the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron&#146;s media and investor relations website (<FONT
STYLE="font-family:arial; font-size:7pt" COLOR="#0563c1"><U>https://investor.regeneron.com</U></FONT><FONT STYLE="font-family:arial">) and its LinkedIn page
(</FONT><FONT STYLE="font-family:arial; font-size:7pt" COLOR="#0563c1"><U>https://</U></FONT><FONT STYLE="font-family:arial; font-size:7pt" COLOR="#0563c1"><U>www.linkedin.com/company/rege</U></FONT><FONT
STYLE="font-family:arial; font-size:7pt" COLOR="#0563c1"><U>neron-pharmaceuticals</U></FONT><FONT STYLE="font-family:arial">). </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g947351g0530164328702.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947351g0530164328702.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I )(# 2(  A$! Q$!_\0
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M:E&DD;#AE,@!!KZ*^ FES:=\,UFF4J;VYDN$!_NX"@_CM-?/7@K_ )*CH?\
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/=X.&5 "/S%%>@T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g947351g0530164329315.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947351g0530164329315.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  0 #D# 2(  A$! Q$!_\0
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7"_=_FG_Q5;4\15IQY82LBXU)15DS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g947351g0530164748024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947351g0530164748024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I )(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BO-?B-\
M7]/\#W']FVT OM5*AFCW82('IN/J?2O)G_:&\6M*66WL%3/W/+/^- 'U'17A
M'AC]HE+J[AM=>TKR_,8()K4DX)..5/\ 2O<Y[B&UMY+B>18X8U+N[G 4#J30
M!)17A'BG]HF&VNY+;PYIZ7*(<?:;@D*WN%';ZUS=M^T9XECE!N-.T^5.ZA6!
M_G0!]-T5YK\.OB]9>.]0;3&L)+.^6(RXW;D8 @'![=16C\1?B98_#Z*U6>TE
MNKJ[#&*-&V@!<9)/XT =S17S1>_M'>())/\ 0]+L84[!]S'^=6M'_:/U)+A5
MUC2+>6 GYFMR58#\<B@#Z-HK-T'7;#Q+HUOJNF3>;:SKE3W![@CL16+XY^(&
MD>!-.6>_8RW,N?(M8S\S^_L/>@#K**^9KS]HWQ#)<%K33+&&'/"N&8_B<UUW
M@[]H&RU6]BL?$-HEB\A"K<QL3'G_ &@>1]: /:Z^<_BE\9M8_P"$@N="\,W!
MM+>UD,,MS&,R2R#@@'L >..3BOHL,&3<I!!&01T-?"UMJ;:=XJCU1XEN&M[P
M7!CDZ.5?=@_6@#T_P=:_%:7Q7H\M[<:^EC-<QF=YYF*>7D%MRD^F>HKL_BGK
MWB33_%4<%I=7=K9B)&A\ABH<]R2.ISQBJ7A/X\ZCXA\5Z9H\VCVL4=Y.L1=&
M;*Y[C)K0^)7Q@NO!WBUM'BT>TNDCA2423$YRU=F!Q4<-5]I*',K;&M&HJ<N9
MJYVNE:GXHETBRDFLD:1[>-G9QAB2HR2.QHIFC^.'U+1+"^>R5&N;:.8JK< L
MH.!^=%3+$1;;Y$)S3>R/EKX@-.WQ(\0&]#;_ .T)00>NS<=N/^ XQ7T#X7M?
MA-KVD0VUA:Z:24 ,5Q@2@X[Y[U+\0?AIX:\;:J9$U&*QUTJ%.U@?,QTW+ZX[
MUX[X@^"7C#0%>XMX%OX8\G?:ME@!WV]:YG%K=$--'LMK\$/#%GXLL==L6E2&
MWD\W[(3N1F'W3GT!YQ6?^T+KT^F>#+33+=RAU*<K*0>L:#)'XDK7DG@/XK:[
MX0U6&"^N9KO2]X2>"8EF09Y*D\@CTKTO]HRR:^\*:)JUO^\MX;A@S+TVR*"#
M]/E_6D(X_P""/PYT[Q8U[J^LQ^=9VL@AC@SP[XR2?8 C\Z]&^)OP[\*6?P_U
M>_M-'M[>ZM8-\4D0VD'(KD_V>O%^FZ?;ZAX?OKB.WFFF%Q;F0X#DJ%9<^OR@
MUZ7\6-0LD^&.NQM=0AY;?:B[QEB6' H \/\ V?/^2F'_ *\9?YK70?M+?\A7
MP_\ ]<)O_0EKG_V?/^2F'_KQE_FM=!^TM_R%?#__ %PF_P#0EH V/@GX&\-Z
MSX%74]2TJ"[NWN9$+RC. ,8 K!^._@+1/#ECIVKZ/;+:&><P2Q)]T_*6! [=
M#7?_   _Y)?%_P!?<W\Q61^TC_R)VD_]A#_VFU $?[-MS+)X9UFV9B8XKM60
M'L63G_T$5X]\2M:N?$_Q)U1RS.J7)M+=,\!4;:,?4C/XUZW^S5_R ]>_Z^8O
M_037C?C:QN/#GQ)U:.1"'AOVGCR/O*6WJ?R(H ^D_#?P=\*:/HD-K>:9#?79
MC'GSS#)9N^/05X?\9_ 5GX*U^TETP%-/OT9DC)SY;J1N ]N0:^E_#OBW1_$V
MC0:E8WD)21 SH7 :,]U([$5\_?M ^*[#7-=T[2]/G2=-/1S-(ARN]\?+GV"C
M\Z /5_@GKT^N_#6V^TN7FLI'M"Q/)"X*_P#CK ?A7S5X4M8+WXC:3:W,2RP3
M:E&DD;#AE,@!!KZ*^ FES:=\,UFF4J;VYDN$!_NX"@_CM-?/7@K_ )*CH?\
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/=X.&5 "/S%%>@T4 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
